A comprehensive analysis of the molecular characteristics of gliomas—the most common malignant brain tumor—explains why some patients diagnosed with slow-growing (low-grade) tumors quickly succumb to the disease while others with more aggressive (high-grade) tumors survive for many years.
Dr. Andrea Califano has won a two-year $200,000 research grant for neuroendocrine cancer research.
KEYTRUDA is an immunotherapy that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, helping the immune system to help detect and fight cancer cells.
The Columbia Combined Cancer Panel has been granted full approval by the New York State Department of Health.
Columbia scientists have created new decoy drugs that can intercept the deceptive growth signals that cancer cells send out.